NVAX earnings analysis
What we found in NVAX's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
Novavax reported significant declines in both revenue and earnings for Q1 2026 compared to Q1 2025. Revenue fell to $139.5 million from $666.7 million year-over-year, exacerbated by a sharp drop in product sales as commercialization transitioned to Sanofi. Operating expenses increased slightly, but the company made substantial progress in aligning its R&D strategy with its revenue generation model through new licensing agreements and restructuring efforts.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Significant Revenue Decline
- Revenue decreased to $139.5 million in Q1 2026, a drop of $527.1 million from $666.7 million in Q1 2025.
- Transition of Sales to Sanofi
- Product sales collapsed to $42.2 million from $621.7 million year-over-year, driven by the transition of Nuvaxovid sales to Sanofi.
- Strong Growth in Licensing Revenue
- Licensing, royalties, and other revenue surged to $97.3 million, up $52.3 million from $45 million in Q1 2025, thanks to the Pfizer License Agreement.
- Cost Containment Strategy
- Despite revenue drops, Novavax effectively reduced SG&A expenses by $19.3 million, from $48.1 million in Q1 2025 to $28.8 million in Q1 2026.
- Operational Cash Use Reduced
- Net cash used in operating activities improved significantly, decreasing to $32.4 million in Q1 2026 from $185.5 million a year earlier, indicating more effective cash management.
- Cash Position Improved
- Cash, cash equivalents, and marketable securities rose to $794.9 million as of March 31, 2026, up from $750.5 million at year-end 2025.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Revenue Instability Post-Transition
- With the transition to Sanofi, reliance on commercial product sales has increased uncertainty around future revenue streams.
- Potential Refunds due to APAs
- Up to $92.5 million in deferred revenue from the Australia APA could become refundable if regulatory approvals fail.
- Liquidity Concerns Amid Restructuring
- The company’s restructuring efforts and reliance on external funding raise caution about liquidity and operational sustainability.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $-0.06
What they said about what is next.
Management provided no specific numeric guidance, citing uncertain market dynamics.
The filing reads worse than the one before it.
What came before.
- 10-K · February 26, 2026
- Novavax’s 2025 10‑K shows a pronounced revenue recovery driven by COVID-19 product sales and one‑time APA adjustments: reported quarterly revenue totaled approximately $1,123.0 million in 2025 (Q1 $667M, Q2 $239M, Q3…
- 10-Q · November 6, 2025
- Novavax reported quarterly revenue of $70.445M (three months ended Sept 30, 2025) vs $84.512M in Q3 2024, and a net loss of $202.379M (diluted EPS $(1.25)). Product sales plunged while licensing/royalties increased.…
- 10-Q · August 6, 2025
- Novavax reported Q2 revenue of $239,240,000 and diluted EPS of $0.62, with strong gross margin of 93.6% and operating margin of 42.3%. The company generated substantial six‑month net income of $625,154,000 but used cash…
- 10-Q · May 8, 2025
- Novavax reported a very strong quarter driven by COVID-19 vaccine sales: total revenue of $666.7 million (Q1 2025) versus $93.9 million (Q1 2024), producing operating income of $515.5 million and diluted EPS of $2.93…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing NVAX makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever